Improving cardiovascular health of patients with chronic kidney disease
The TRACK trial will evaluate whether a small dose of rivaroxaban, a blood-thinning
medication, would reduce cardiovascular death or major cardiovascular events
in patients with advanced stages of chronic kidney disease.
Low dose rivaroxaban reduced the risk of cardiovascular and limb outcomes including acute limb ischaemia and major vascular amputation. @TRACK_trial is evaluating low dose rivaroxaban in patients with CKD stage 4,5 and dialysis.